Coherus BioSciences (CHRS) Reports Q4 Loss of $1.72/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Coherus BioSciences Reports Second Quarter 2016 Financial and Operating Results
August 9, 2016 4:01 PM EDTREDWOOD CITY, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today reported financial results and reviewed corporate events for the second quarter ended June 30, 2016.
Corporate Highlights for the Second Quarter 2016 Include:
Immunology (anti-TNF) therapeutic franchise: CHS-1420 (adalimumab (HUMIRA®) biosimilar) Received favorable decision from the Patent Trial and Review Board (PTAB) for the United States Patent and Trademark Office (USPTO) instituting Coherus' petition for Inter Partes Review (IPR) of AbbVies U.S. patent 8,889,135 (the 135 patent), 9,017,680 and 9,073,987 (patents 680 and 987, respectively), which are all related to the dosing regimen for... More